Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27737779 | 0.94 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBTP53ALDH1A1CHRNB2 | |
| SCHEMBL1127208 | 0.88 | — | — | |
| SCHEMBL14146570 | 0.88 | — | — | |
| SCHEMBL27694371 | 0.85 | HDAC3 (0.35) | SMN1; SMN2POLBTP53ALDH1A1HDAC3 | |
| SCHEMBL27492890 | 0.80 | HDAC3 (0.36) | SMN1; SMN2HDAC3HDAC1HDAC2 | |
| SCHEMBL11301518 | 0.79 | ALDH1A1 (0.47) | SMN1; SMN2POLBALDH1A1PPM1BPTPN1 | |
| SCHEMBL12191578 | 0.78 | — | — | |
| SCHEMBL20012114 | 0.78 | TSHR (0.35) | SMN1; SMN2POLBALDH1A1HDAC3HDAC1 | |
| SCHEMBL27714334 | 0.77 | SMN1; SMN2 (0.53) | SMN1; SMN2POLBTP53ALDH1A1CHRNB2 | |
| SCHEMBL15116660 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0060955-A1 | Substituted uracils containing a 2-tetrahydropyranyl group, process for their preparation and pesticidal compositions containing them | ROUSSEL-UCLAF (FR) | 1982-09-29 | — | — | EP | claimed |
| WO-2026090509-A1 | SPIRO HETEROCYCLIC CDK2 INHIBITORS | ARCHITECT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024216154-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-10-17 | — | — | WO | disclosed |
| CN-116234550-A | Aromatic formyl substituted tricyclic compound and preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-114599640-A | Isoxazole carboxylic acids as LPA antagonists | 百时美施贵宝公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114599648-A | Triazole carboxylic acids as LPA antagonists | 百时美施贵宝公司 | 2022-06-07 | — | — | CN | disclosed |
| WO-2022063101-A1 | AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-03-31 | — | — | WO | disclosed |
| WO-2020257135-A1 | TRIAZOLE CARBOXYLIC ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-24 | — | — | WO | disclosed |
| US-10472392-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| CN-105085515-B | Hydrazide kind compound as coagulation factor xa inhibitors | 华北制药股份有限公司 | 2019-02-01 | — | — | CN | disclosed |
| US-9340538-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-05-17 | — | — | US | disclosed |
| US-9315522-B2 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-19 | — | — | US | disclosed |
| US-9296760-B2 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-29 | — | — | US | disclosed |
| US-20150225424-A1 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-13 | — | — | US | disclosed |
| US-20150210719-A1 | ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND US (IE) | 2015-07-30 | — | — | US | disclosed |
| US-20150152096-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-06-04 | — | — | US | disclosed |
| CN-101268074-A | 5-amino-4-hydroxy-7- (imidazo [1,2-A] pyridin-6- ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension | SPEEDEL EXPERIMENTA AG (CH) | 2008-09-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152096-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | DPYD, SLC10A1, HPRT1 | SMN1; SMN2 1778/4885POLB 290/4885TP53 93/4885 |
| US-10472392-B2 | Macrocyclic inhibitors of flaviviridae viruses | HAVCR2, ZC3HAV1, HCCS | SMN1; SMN2 1414/4885POLB 1987/4885TP53 3215/4885 |
| US-20150210719-A1 | ANTIBACTERIAL COMPOUNDS | FAR1, GAA, ECI1 | SMN1; SMN2 4531/4885POLB 527/4885TP53 4714/4885 |
| US-20150225424-A1 | Antibacterial compounds | FAR1, GAA, ECI1 | SMN1; SMN2 4531/4885POLB 527/4885TP53 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.